羟考酮缓释片联合吗啡针在中重度癌痛阿片类药物剂量滴定中的临床研究

Effects of Dose Titration with controlled-release oxycodone and morphine hydrochloride injection on patients with moderate to severe cancer pain

目的探讨盐酸羟考酮缓释片联合盐酸吗啡针滴定癌痛的疗效及不良反应。方法 90例住院中重度癌痛患者应用盐酸羟考酮缓释片联合吗啡针滴定,记录滴定完成所需要的时间,观察滴定开始后第7天的疼痛控制有效率,滴定前、后的疼痛强度变化以及滴定中的不良反应。疼痛强度评分应用数字分级法。结果 87.8%的患者在3天内完成滴定。滴定后第7天患者疼痛控制率达96.7%。滴定中不良反应主要为便秘(27.8%)、恶心呕吐(13.3%)、嗜睡(4.4%),除便秘外经过对症处理均可耐受。结论盐酸羟考酮缓释片联合吗啡针滴定中重度癌痛患者达到良好滴定效果,不良反应较轻。

Objective To explore the efficacy and adverse events of controlled - releaseoxycodone （CRoxycodone） and morphine hydrochloride injection during the dose titration. Methods A total of 90 patients with moderate to severe cancer pain were titrated with oxycodone hydrochloridecontrolled - release tablets and morphine hydrochloride injection. Data were recorded including the degree of painrelief, and adverse events. Pain intensity was assessed using a Numerical RatingScale（0 - 10）. The continuous observation period lasted for 1 week. Results 87. 8% of patients achieved stable analgesic dose within 3 days. Painremission rate of 7 days after medication were 96. 7%. Commonly reported adverse e-vents were constipation （28. 7% ）, nausea andvomiting （ 13.3% ）, and somnolence （4. 4% ）. No serious adverse events took place. Conclusion Dose titration with CR oxycodone and morphine hydrochloride injection can be accomplished safely and effectively for patients with moderate to severe cancer pain.